Form 4: Edwards Lifesciences Exec Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, executed a pre-planned sale of 11,340 common shares following an option exercise.

Summary

• Donald E. Bobo Jr., CVP, Strategy/Corp Development at Edwards Lifesciences Corp (EW), reported transactions on March 2, 2026.
• The transactions involved the exercise of 11,340 employee stock options at an exercise price of $59.2567 per share.
• Concurrently, 11,340 shares of common stock were sold at a weighted average price of $85.9286 per share, with prices ranging from $85.665 to $86.380.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Bobo on February 27, 2025.
• Following these transactions, Mr. Bobo directly owns 21,266.2532 shares of common stock.
• Indirect beneficial ownership includes 38,900.5862 shares in a 401(k) and 121,756 shares held by a Trust.
• Mr. Bobo retains 22,680 employee stock options (right to acquire) after the reported exercise.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure. Form 4 filings report factual insider transactions and do not typically contain information that directly impacts the company's operational sentiment.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving option exercises followed by sales, are common and often executed under pre-arranged Rule 10b5-1 trading plans. These plans allow insiders to sell shares at predetermined times or prices to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may note the insider sale, but given it was executed under a Rule 10b5-1 plan, it is generally considered a routine liquidity event rather than a signal of management's view on future company performance.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-established Rule 10b5-1 trading plan. Such transactions are common for executives and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation. Investors should consider this a standard disclosure rather than a signal for immediate action.

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, Donald E. Bobo Jr., Rule 10b5-1